Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression

(MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized anxiety disorder (GAD) and major depressive...

Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Saturday 7 November →